🚀 VC round data is live in beta, check it out!
Madrigal Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Madrigal Pharmaceuticals and similar public comparables like Samchundang Pharm, Zydus Lifesciences, Wuxi XDC, Mankind Pharma and more.
Madrigal Pharmaceuticals Overview
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Founded
2011
HQ
Employees
528
Website
Sectors
Financials (LTM)
EV
$9B
Madrigal Pharmaceuticals Financials
Madrigal Pharmaceuticals reported last 12-month revenue of $1B.
In the same LTM period, Madrigal Pharmaceuticals generated $1B in gross profit and had net loss of ($253M).
Revenue (LTM)
Madrigal Pharmaceuticals P&L
In the most recent fiscal year, Madrigal Pharmaceuticals reported revenue of $958M and EBITDA of ($264M).
Madrigal Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $958M | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $902M | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | 94% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($264M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (28%) | XXX | XXX | XXX |
| EBIT Margin | (24%) | XXX | (31%) | XXX | XXX | XXX |
| Net Profit | ($253M) | XXX | ($288M) | XXX | XXX | XXX |
| Net Margin | (24%) | XXX | (30%) | XXX | XXX | XXX |
| Net Debt | — | — | $141M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Madrigal Pharmaceuticals Stock Performance
Madrigal Pharmaceuticals has current market cap of $10B, and enterprise value of $9B.
Market Cap Evolution
Madrigal Pharmaceuticals' stock price is $435.62.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9B | $10B | 0.0% | XXX | XXX | XXX | $-12.69 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMadrigal Pharmaceuticals Valuation Multiples
Madrigal Pharmaceuticals trades at 8.5x EV/Revenue multiple, and (34.5x) EV/EBITDA.
EV / Revenue (LTM)
Madrigal Pharmaceuticals Financial Valuation Multiples
As of March 21, 2026, Madrigal Pharmaceuticals has market cap of $10B and EV of $9B.
Equity research analysts estimate Madrigal Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Madrigal Pharmaceuticals has a P/E ratio of (39.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10B | XXX | $10B | XXX | XXX | XXX |
| EV (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV/Revenue | 8.5x | XXX | 9.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (34.5x) | XXX | XXX | XXX |
| EV/EBIT | (35.1x) | XXX | (30.4x) | XXX | XXX | XXX |
| EV/Gross Profit | 9.1x | XXX | 10.1x | XXX | XXX | XXX |
| P/E | (39.1x) | XXX | (34.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (47.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Madrigal Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Madrigal Pharmaceuticals Margins & Growth Rates
Madrigal Pharmaceuticals' revenue in the last 12 month grew by 52%.
Madrigal Pharmaceuticals' revenue per employee in the last FY averaged $2.0M.
Madrigal Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 52% | XXX | 54% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (28%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (62%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $2.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 85% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 36% | XXX | 41% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 126% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Madrigal Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Samchundang Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Zydus Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Wuxi XDC | XXX | XXX | XXX | XXX | XXX | XXX |
| Mankind Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Baxter International | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Madrigal Pharmaceuticals M&A Activity
Madrigal Pharmaceuticals acquired XXX companies to date.
Last acquisition by Madrigal Pharmaceuticals was on XXXXXXXX, XXXXX. Madrigal Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Madrigal Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMadrigal Pharmaceuticals Investment Activity
Madrigal Pharmaceuticals invested in XXX companies to date.
Madrigal Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Madrigal Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Madrigal Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Madrigal Pharmaceuticals
| When was Madrigal Pharmaceuticals founded? | Madrigal Pharmaceuticals was founded in 2011. |
| Where is Madrigal Pharmaceuticals headquartered? | Madrigal Pharmaceuticals is headquartered in United States. |
| How many employees does Madrigal Pharmaceuticals have? | As of today, Madrigal Pharmaceuticals has over 528 employees. |
| Who is the CEO of Madrigal Pharmaceuticals? | Madrigal Pharmaceuticals' CEO is William John Sibold. |
| Is Madrigal Pharmaceuticals publicly listed? | Yes, Madrigal Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Madrigal Pharmaceuticals? | Madrigal Pharmaceuticals trades under MDGL ticker. |
| When did Madrigal Pharmaceuticals go public? | Madrigal Pharmaceuticals went public in 2007. |
| Who are competitors of Madrigal Pharmaceuticals? | Madrigal Pharmaceuticals main competitors are Samchundang Pharm, Zydus Lifesciences, Wuxi XDC, Mankind Pharma. |
| What is the current market cap of Madrigal Pharmaceuticals? | Madrigal Pharmaceuticals' current market cap is $10B. |
| What is the current revenue of Madrigal Pharmaceuticals? | Madrigal Pharmaceuticals' last 12 months revenue is $1B. |
| What is the current revenue growth of Madrigal Pharmaceuticals? | Madrigal Pharmaceuticals revenue growth (NTM/LTM) is 52%. |
| What is the current EV/Revenue multiple of Madrigal Pharmaceuticals? | Current revenue multiple of Madrigal Pharmaceuticals is 8.5x. |
| Is Madrigal Pharmaceuticals profitable? | No, Madrigal Pharmaceuticals is not profitable. |
| What is the current net income of Madrigal Pharmaceuticals? | Madrigal Pharmaceuticals' last 12 months net income is ($253M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.